|Bid||84.80 x 300|
|Ask||0.00 x 0|
|Day's Range||83.86 - 85.23|
|52 Week Range||53.15 - 85.23|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.
Biotech has been on a tear recently, and Barclays’ Paul Choi and Geoff Meacham write that investor will probably stay positive on the sector. They attribute the recent rally to the expectation that more ...
RBC Capital Markets just launched coverage of the biotech sector, covered by Brian Abrahams, Kennen MacKay, and Matthew Eckler, and they spoke with Barrons.com about the industry, which they say is seeing a number of exciting innovations as we enter a new era of personalized medicine. Of course, biotech has been on a wild ride in recent years, but after being shunned by a number of investors previously, the sector is seeing new life in 2017, with the Nasdaq Biotechnology Index (NBI) up more than 25% this year, and SPDR S&P Biotech ETF (XBI) up more than 40%.